Biogen Inc
FDA advisors weigh whether Alzheimer’s drug Leqembi should receive full approval
[The stream is scheduled to begin at 10 a.m. ET. Please refresh the page if you don’t see a player above at that time.] A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer’s drug Leqembi, made by Eisai and Biogen, should receive […]
Read More
Bernie Sanders says price of Alzheimer’s treatment is unconscionable, calls on HHS to take action
Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC. Anna Moneymaker | Getty Images Sen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to ensure seniors can actually afford the expensive Alzheimer’s treatment Leqembi. Sanders, who chairs the Senate […]
Read More
Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and Metabolic […]
Read More
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | Reuters The new Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research published in a leading medical journal this week. Medicare would spend about $2 billion per year […]
Read More
Shares producing the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & extra
In this short article GNRC CCOI PACW Follow your most loved stocksGenerate No cost ACCOUNT basic watch of a Starbucks retail outlet on September 15, 2022 in Plainview, New York Bruce Bennett | Getty Visuals Information | Getty Illustrations or photos Verify out the businesses making headlines in premarket trading. Eli Lilly — The pharmaceutical […]
Read More
Bipartisan attorneys general call on Medicare to cover Alzheimer’s treatments
The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Democratic and Republican attorneys general in nearly half of U.S. states are calling on Medicare to provide unrestricted coverage of antibody treatments for Alzheimer’s disease, according to a letter released Monday. The push […]
Read More
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Juanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the coming years, putting them at risk of developing more severe disease as they wait months or perhaps years for a diagnosis. The U.S. health-care system is […]
Read More
Alzheimer’s: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021. Caroline Brehman | CQ-Roll Call, Inc. | Getty Images Medicare will cover the new Alzheimer’s treatment Leqembi for all patients eligible under the medication’s label […]
Read More
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there are […]
Read More